Reports
Sale
Neuroendocrine Carcinoma Market Size, Share, Trends, Report: By Treatment Type: Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy, Others; By Indication: Lungs, Pancreas, Gastrointestinal, Others; By End User; Regional Analysis; Market Dynamics; Patent Analysis; Grants Analysis; Supplier Landscape;2024-2032
Neuroendocrine Carcinoma Market Outlook
The neuroendocrine carcinoma market size was valued at USD 2.44 billion in 2023, driven by the rising prevalence of personalised medicine across the major markets. The market is expected to grow at a CAGR of 10.03% during the forecast period of 2024-2032, with the values likely to rise from USD 2.7 billion in 2024 to USD 5.8 billion by 2032.
Neuroendocrine Carcinoma: Introduction
Neuroendocrine carcinoma, also referred to as neuroendocrine tumour or neoplasm, initiates in specialized cells of the neuroendocrine system. These cells are present throughout the body and possess the traits of nerve cells as well as hormone producing endocrine cells. This tumour can affect any part of the body, including lungs, pancreas, and the GI (gastrointestinal) tract. Symptoms may vary depending upon the tumor location.
Neuroendocrine Carcinoma Market Analysis
As neuroendocrine carcinoma affects the hormone cells of the body, the repercussions range from skin rashes to diarrhoea to low or high blood pressure. In such cases, somatostatin analogues like octreotide and lanreotide are used. Chemotherapy, targeted therapy, peptide receptor radionuclide therapy are other non-pharmacological interventions used to treat the condition and aid in catering to the rising neuroendocrine carcinoma market demand.
With a specific focus on treating liver NET, radioembolization is being applied to slow down the tumour growth and shrink by directly offering radiation to the liver. This is done with the help of small radioactive particles, lodged inside the tumour to inhibit blood flow and emit radiation, damaging the cancer cells.
The neuroendocrine carcinoma market growth is driven by the increasing collaborations in prominent companies to expand their product portfolio and offer improved treatment alternatives to patients. In October 2023, Eli Lilly and Company acquired Point Biopharma Global to develop radioligand therapy for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The acquisition costed around USD 1.4 billion, which is an indicator that the market is experiencing hefty investments to foster innovation.
Neuroendocrine Carcinoma Market Segmentation
Market Breakup by Treatment Type
- Somatostatin Analogs (SSAs)
- Targeted Therapy
- Chemotherapy
- Others
Market Breakup by Indication
- Lungs
- Pancreas
- Gastrointestinal
- Others
Market Breakup by End User
- Hospitals
- Clinics
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Neuroendocrine Carcinoma Market Overview
The United States has dominated the neuroendocrine carcinoma market share, driven by the rising collaborations between research and academic institutions. In June 2023, Stanford University’s Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories (Intonation) collaborated to develop treatments for cancerous neuroendocrine tumors. With a robust healthcare infrastructure, the region is expected to lead the market in the forecast period as well.
Europe is another major market with numerous well-equipped healthcare and research infrastructure to foster new therapies for neuroendocrine carcinoma treatment. Major collaborations amongst healthcare companies are also contributing to the market value.
With continuously improving medical ecosystem, the Asia Pacific region, particularly Japan, is anticipated to experience maximum neuroendocrine carcinoma market growth. To leverage the academic talent and other resources, countries with emerging economies like India, and South Korea are also witnessing an influx of foreign capital. Such investments may boost the market growth significantly in the forecast period.
Neuroendocrine Carcinoma Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb
- Eli Lilly & Company
- F. Hoffmann-La Roche Ltd.
- Ipsen
- Baxter
- Novartis AG
- Pfizer Inc.
- Lantheus Holdings, Inc.
- Tarveda Therapeutics
- AVEO Pharmaceuticals, Inc.
- Advanced Accelerator Applications
- BioSynthema Inc.
- Merck Sharp & Dohme Corp.
- Bionano Genomics
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Indication |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Neuroendocrine Carcinoma Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Neuroendocrine Carcinoma Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Neuroendocrine Carcinoma Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Neuroendocrine Carcinoma Epidemiology Forecast (2017-2032)
5.3.1 Germany Neuroendocrine Carcinoma Epidemiology Forecast (2017-2032)
5.3.2 France Neuroendocrine Carcinoma Epidemiology Forecast (2017-2032)
5.3.3 Italy Neuroendocrine Carcinoma Epidemiology Forecast (2017-2032)
5.3.4 Spain Neuroendocrine Carcinoma Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Neuroendocrine Carcinoma Epidemiology Forecast (2017-2032)
5.4 Japan Neuroendocrine Carcinoma Epidemiology Forecast (2017-2032)
6 Neuroendocrine Carcinoma Market Overview – 7MM
6.1 Neuroendocrine Carcinoma Market Historical Value (2017-2023)
6.2 Neuroendocrine Carcinoma Market Forecast Value (2024-2032)
7 Neuroendocrine Carcinoma Market Landscape – 7MM
7.1 Neuroendocrine Carcinoma Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Neuroendocrine Carcinoma Product Landscape
7.2.1 Analysis by Products
7.2.2 Analysis by Indications
7.2.3 Analysis by Route of Administration
8 Neuroendocrine Carcinoma Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Neuroendocrine Carcinoma Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Neuroendocrine Carcinoma Market Segmentation – 7MM
11.1 Neuroendocrine Carcinoma Market by Treatment Type
11.1.1 Market Overview
11.1.2 Somatostatin Analogs (SSAs)
11.1.3 Targeted Therapy
11.1.4 Chemotherapy
11.1.5 Others
11.2 Neuroendocrine Carcinoma Market by Indication
11.2.1 Market Overview
11.2.2 Lungs
11.2.3 Pancreas
11.2.4 Gastrointestinal
11.2.5 Others
11.3 Neuroendocrine Carcinoma Market by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Clinics
11.3.4 Others
11.4 Neuroendocrine Carcinoma Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
12 United States Neuroendocrine Carcinoma Market
12.1 Neuroendocrine Carcinoma Market Historical Value (2017-2023)
12.2 Neuroendocrine Carcinoma Market Forecast Value (2024-2032)
12.2.1 Neuroendocrine Carcinoma Market by Indication
12.2.2 Neuroendocrine Carcinoma Market by Treatment Type
13 EU-4 and United Kingdom Neuroendocrine Carcinoma Market
13.1 Neuroendocrine Carcinoma Market Historical Value (2017-2023)
13.2 Neuroendocrine Carcinoma Market Forecast Value (2024-2032)
13.3 Germany Neuroendocrine Carcinoma Market Overview
13.3.1 Neuroendocrine Carcinoma Market by Indication
13.3.2 Neuroendocrine Carcinoma Market by Treatment Type
13.4 France Neuroendocrine Carcinoma Market Overview
13.4.1 Neuroendocrine Carcinoma Market by Indication
13.4.2 Neuroendocrine Carcinoma Market by Treatment Type
13.5 Italy Neuroendocrine Carcinoma Market Overview
13.5.1 Neuroendocrine Carcinoma Market by Indication
13.5.2 Neuroendocrine Carcinoma Market by Treatment Type
13.6 Spain Neuroendocrine Carcinoma Market Overview
13.6.1 Neuroendocrine Carcinoma Market by Indication
13.6.2 Neuroendocrine Carcinoma Market by Treatment Type
13.7 United Kingdom Neuroendocrine Carcinoma Market Overview
13.7.1 Neuroendocrine Carcinoma Market by Indication
13.7.2 Neuroendocrine Carcinoma Market by Treatment Type
14 Japan Neuroendocrine Carcinoma Market
14.1 Neuroendocrine Carcinoma Market Historical Value (2017-2023)
14.2 Neuroendocrine Carcinoma Market Forecast Value (2024-2032)
14.3 Neuroendocrine Carcinoma Market by Indication
14.4 Neuroendocrine Carcinoma Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Boehringer Ingelheim International GmbH
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisitions
20.1.5 Certifications
20.2 Bristol-Myers Squibb
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisitions
20.2.5 Certifications
20.3 Eli Lilly & Company
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisitions
20.3.5 Certifications
20.4 F. Hoffmann-La Roche Ltd.
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisitions
20.4.5 Certifications
20.5 Ipsen
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisitions
20.5.5 Certifications
20.6 Baxter
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisitions
20.6.5 Certifications
20.7 Novartis AG
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisitions
20.7.5 Certifications
20.8 Pfizer Inc.
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisitions
20.8.5 Certifications
20.9 Lantheus Holdings, Inc.
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisitions
20.9.5 Certifications
20.10 Tarveda Therapeutics
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisitions
20.10.5 Certifications
20.11 AVEO Pharmaceuticals, Inc.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisitions
20.11.5 Certifications
20.12 Advanced Accelerator Applications
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisitions
20.12.5 Certifications
20.13 BioSynthema Inc.
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisitions
20.13.5 Certifications
20.14 Merck
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisitions
20.14.5 Certifications
20.15 Bionano Genomics
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisitions
20.15.5 Certifications
21 Neuroendocrine Carcinoma Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 2.44 billion in 2023, driven by the rising prevalence of personalised medicines across the major markets.
The market is anticipated to grow at a CAGR of 10.03% during the forecast period of 2024-2032, likely to reach a market value of USD 5.8 billion by 2032.
The market demand is driven by increasing application of technically aided therapeutics other than pharmacological interventions.
The current market trend involves rising mergers and acquisitions between proficient companies to expand research and innovation possibilities. In October 2023, Eli Lilly and Company acquired Point Biopharma Global to develop radioligand therapy for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
The treatment type can be divided into Somatostatin Analogs (SSAs), Targeted Therapy, and Chemotherapy, among Others.
The indications can be categorized into lungs, pancreas, and gastrointestinal, among others.
The end-users in the market include hospitals and clinics, among others.
The major regions of the market include the United States, Japan, EU-4 and the United Kingdom. EU-4 is segmented into Germany, France, Italy, and Spain.
Key players involved in the market are Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly & Company, F. Hoffmann-La Roche Ltd., Ipsen, Baxter, Novartis AG, Pfizer Inc., Lantheus Holdings, Inc., Tarveda Therapeutics, AVEO Pharmaceuticals, Inc., Advanced Accelerator Applications, BioSynthema Inc., Merck Sharp & Dohme Corp., and Bionano Genomics.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER